Literature DB >> 12859406

Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.

C I Scott1, D G Iorgulescu, H J Thorne, M A Henderson, K A Phillips.   

Abstract

Prophylactic mastectomy (PM) is a risk-management option for women at high familial risk of breast cancer (BC). This study describes the PM experience of women enrolled in a large observational cohort study involving families with a history of hereditary breast cancer. Within 357 multiple-case BC families [119 (33%) BRCA1 or BRCA2 mutation positive], identified via family cancer clinics, 49 cases of PM [21 (43%) BRCA1 or BRCA2 mutation positive] were identified and their clinical, pathological and genetic features reviewed. Families with at least one incidence of PM displayed stronger breast/ovarian cancer histories than did families without PM. Median age at time of PM was 45 years (range 28-58). Ten cases (21%) were bilateral PMs in unaffected women and 39 cases were contralateral PMs in women with prior invasive BC (71%) or ductal carcinoma in situ (DCIS) (8%). Most (88%) underwent total mastectomy. Unnecessary axillary surgery occurred in eight subjects (16%). Malignant histology was found in three PM specimens (6%). Prior to genetic testing, PM was performed in two women who were subsequently shown not to carry the mutation specific to their family. Optimal utilization of genetic testing to guide surgical decision making, appropriate surgical technique and careful pathology examination of PM specimens, are important issues to consider prior to PM in women at high familial risk of BC.

Entities:  

Mesh:

Year:  2003        PMID: 12859406     DOI: 10.1034/j.1399-0004.2003.00097.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile.

Authors:  K Graham; A de las Morenas; A Tripathi; C King; M Kavanah; J Mendez; M Stone; J Slama; M Miller; G Antoine; H Willers; P Sebastiani; C L Rosenberg
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 2.  Risk-reducing mastectomy for the prevention of primary breast cancer.

Authors:  Nora E Carbine; Liz Lostumbo; Judi Wallace; Henry Ko
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05

3.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Authors:  Graham J Mann; Heather Thorne; Rosemary L Balleine; Phyllis N Butow; Christine L Clarke; Edward Edkins; Gerda M Evans; Sián Fereday; Eric Haan; Michael Gattas; Graham G Giles; Jack Goldblatt; John L Hopper; Judy Kirk; Jennifer A Leary; Geoffrey Lindeman; Eveline Niedermayr; Kelly-Anne Phillips; Sandra Picken; Gulietta M Pupo; Christobel Saunders; Clare L Scott; Amanda B Spurdle; Graeme Suthers; Kathy Tucker; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2006-02-13       Impact factor: 6.466

4.  Ductal-lobar organisation of human breast tissue, its relevance in disease and a research objective: vector mapping of parenchyma in complete breasts (the Astley Cooper project).

Authors:  James J Going
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

5.  Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.

Authors:  Jacob G Comeaux; Julie O Culver; John E Lee; Danielle Dondanville; Heather L McArthur; Emily Quinn; Nicholas Gorman; Charité Ricker; Ming Li; Caryn Lerman
Journal:  Mol Genet Genomic Med       Date:  2022-08-25       Impact factor: 2.473

6.  Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.

Authors:  Bernadette A M Heemskerk-Gerritsen; Cecile T M Brekelmans; Marian B E Menke-Pluymers; Albert N van Geel; Madeleine M A Tilanus-Linthorst; Carina C M Bartels; Murly Tan; Hanne E J Meijers-Heijboer; Jan G M Klijn; Caroline Seynaeve
Journal:  Ann Surg Oncol       Date:  2007-05-31       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.